Rocket Pharmaceuticals is a biotechnology business based in the US. Rocket Pharmaceuticals shares (RCKT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14.82 – a decrease of 15.07% over the previous week. Rocket Pharmaceuticals employs 268 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $14.82 |
|---|---|
| 52-week range | $13.80 - $32.53 |
| 50-day moving average | $17.91 |
| 200-day moving average | $22.35 |
| Wall St. target price | $46.93 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.58 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.82 from 2024-11-14
| 1 week (2024-11-08) | -15.07% |
|---|---|
| 1 month (2024-10-15) | -11.15% |
| 3 months (2024-08-15) | -20.32% |
| 6 months (2024-05-15) | -37.36% |
| 1 year (2023-11-15) | -32.14% |
|---|---|
| 2 years (2022-11-15) | -28.41% |
| 3 years (2021-11-15) | 25.9 |
| 5 years (2019-11-15) | 1.86% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -34.48% |
| Return on equity TTM | -59.27% |
| Profit margin | 0% |
| Book value | $3.62 |
| Market Capitalization | $1.4 billion |
TTM: trailing 12 months
We're not expecting Rocket Pharmaceuticals to pay a dividend over the next 12 months.
Rocket Pharmaceuticals's shares were split on a 1:4 basis on 4 January 2018 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rocket Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Rocket Pharmaceuticals shares which in turn could have impacted Rocket Pharmaceuticals's share price.
Over the last 12 months, Rocket Pharmaceuticals's shares have ranged in value from as little as $13.8 up to $32.525. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rocket Pharmaceuticals's is 1.089. This would suggest that Rocket Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Rocket Pharmaceuticals, Inc. , together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.